Smith & Nephew SNATS, Inc.
SNN Healthcare Medical Devices
Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow SNN
Smith & Nephew SNATS, Inc. (SNN) EV/Sales
As of 16 October 2026, Smith & Nephew SNATS, Inc. (SNN) trades at a EV/Sales of 1.5×. Over the past ten years it has ranged from 1.1× (September 2022) to 4.1× (April 2018); the current reading is higher than 20% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.7× | 26.89% |
| FY2024 | 1.3× | (2.83%) |
| FY2023 | 1.3× | (5.61%) |
| FY2022 | 1.4× | (18.33%) |
| FY2021 | 1.7× | (16.55%) |
| FY2020 | 2.1× | (20.42%) |
| FY2019 | 2.6× | (11.63%) |
| FY2018 | 3.0× | (19.16%) |
| FY2017 | 3.7× | 13.36% |
| FY2016 | 3.2× | (13.70%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2023 | 1.6× | 14.93% |
| Dec 2022 | 1.4× | (1.75%) |
| Jun 2022 | 1.4× | (18.83%) |
| Dec 2021 | 1.8× | (17.18%) |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNN Smith & Nephew SNATS, Inc. | 1.5× |
| BRKR Bruker Corporation compare | 2.9× |
| ZBH Zimmer Biomet Holdings, Inc. compare | 3.0× |
| PODD Insulet Corporation compare | 3.3× |
| GMED Globus Medical, Inc. compare | 3.4× |
| BIO Bio-Rad Laboratories, Inc. compare | 3.5× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 3.6× |
| PEN Penumbra, Inc. compare | 8.0× |
| GKOS Glaukos Corporation compare | 15.9× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)